


Claims:

1. A compound according to Formula I



(Formula I)

5

or a pharmaceutically acceptable salt thereof wherein

Y is a single carbon-carbon bond or a double carbon-carbon bond, with the proviso that when Y is a double carbon-carbon bond, R₁₅ and R₁₆ are not present;

one of the three positions A₁-A₃ is either S or NR_A, the remaining two positions A₁-A₃ are N or CR₁, CR₂, CR₃,
10 respectively;

R_A is H or methyl;

R₁-R₃ are independently H, methyl, amino or halogen;

A₄-A₇ are CR₄, CR₅, CR₆ and CR₇, respectively;

A₈-A₁₂ are N or CR₈, CR₉, CR₁₀, CR₁₁ and CR₁₂, respectively, with the proviso that no more than two of the
15 five positions A₈-A₁₂ can be simultaneously N;

R₄-R₇ are independently H, halogen, C(1-3)alkoxy, C(1-3)alkyl;

R₈-R₁₂ are independently H, halogen, C(1-3)alkoxy, C(1-4)alkyl, cyano, nitro, -C(=O)OR₁₇, hydroxyl, C(3-6)cycloalkyl, benzyl, phenyl, -SF₅, bicyclo[1.1.1]pentane;

or R₉ and either R₈ or R₁₀ are fused and form an aromatic or non-aromatic five to seven membered ring containing two to seven carbon atoms and zero to three hetero atoms; with all carbon atoms optionally substituted with one or more methyl, halogen or hydroxyl;

R₁₃ is H or methyl;

5 R₁₄ is NH, O or S;

R₁₅ and R'₁₅ are independently H, halogen, C(1-4)alkyl, -C(=O)OR₁₇ or -C(=O)NR₁₇R₁₇;

R₁₆ is H; and,

R₁₇ is H, methyl or ethyl.

2. The compound according to claim 1, wherein A₁ is N, A₂ is NR_A and A₃ is CR₃.

10 3. The compound according to claim 2, wherein A₁ is N, A₂ is NH and A₃ is CH.

4. The compound according to any one of claims 1 to 3, wherein R₅ is C(1-3)alkoxy and R₄, R₆ and R₇ are H.

5. The compound according to claim 4, wherein R₅ is methoxy and R₄, R₆ and R₇ are H.

6. The compound according to any one of claims 1 to 5, wherein A₈-A₁₂ are CR₈, CR₉, CR₁₀, CR₁₁ and CR₁₂ respectively.

15 7. The compound according to claim 6, wherein R₈-R₁₂ are independently H, C(1-4)alkyl, halogen, hydroxyl, C(1-3)alkoxy.

8. The compound according to claim 7, wherein R₉ and R₁₁ are C(1-4)alkyl and R₈, R₁₀ and R₁₂ are H.

9. The compound according to claim 8, wherein R₉ and R₁₁ are CF₃ and R₈, R₁₀ and R₁₂ are H.

10. The compound according to any one of claims 1 to 9, wherein R₁₃ is H.

11. The compound according to any one of claims 1 to 10, wherein R₁₄ is O.

20 12. The compound according to any one of claims 1 to 11, wherein R₁₅ and R'₁₅ are H.

13. The compound according to any one of claims 1 to 12, wherein Y is a single carbon-carbon bond.

14. The compound according to claim 1, which is selected from the group consisting of:

4-[3-methoxy-4-(3-methylphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

4-(2-methoxy-4-{6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl}phenoxy)-3-(trifluoromethyl)benzonitrile;

25 4-[3-methoxy-4-(2-nitrophenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

- 4-{3-methoxy-4-[2-(trifluoromethyl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-{3-methoxy-4-[4-(trifluoromethyl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-{3-methoxy-4-[3-(trifluoromethyl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-bromophenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 5 4-[3-methoxy-4-(2-methylphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 2-(2-methoxy-4-{6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl}phenoxy)benzonitrile;
- 4-[4-(2-*tert*-butylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-chlorophenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-{3-methoxy-4-[2-(trifluoromethoxy)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 10 4-[3-methoxy-4-(2-methoxyphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-bromophenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-*tert*-butylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-chlorophenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-{3-methoxy-4-[3-(trifluoromethoxy)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 15 4-[3-methoxy-4-(3-methoxyphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- methyl 3-(2-methoxy-4-{6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl}phenoxy)benzoate;
- 4-[4-(2-ethylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-ethylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[3-methoxy-4-(2-propylphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 20 4-{3-methoxy-4-[2-(propan-2-yl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[3-methoxy-4-(2-phenylphenoxy)phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-cyclopentylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-benzylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-*tert*-butyl-4-methoxyphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

- 4-[4-(2-cyclopropylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-*tert*-butyl-4-hydroxyphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[3-methoxy-4-[3-(propan-2-yl)phenoxy]phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3-cyclopropylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 5 4-[4-(2-*tert*-butyl-4-ethylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(4-bromo-2-*tert*-butylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-*tert*-butyl-4-methylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- methyl 3-*tert*-butyl-4-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)benzoate;
- methyl 4-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)naphthalene-1-carboxylate;
- 10 4-[4-(2,4-di-*tert*-butylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[3-methoxy-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 3-*tert*-butyl-4-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)benzonitrile;
- 4-[3-methoxy-4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]phenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- methyl 3-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)-5-(trifluoromethyl)benzoate;
- 15 4-[4-[3-bromo-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(3,5-di-*tert*-butylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2-{bicyclo[1.1.1]pentan-1-yl}phenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)naphthalene-1-carbonitrile;
- 20 4-[4-(2,3-dihydro-1H-inden-4-yloxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- 4-[4-(2,3-dihydro-1H-inden-5-yloxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;
- methyl 8-(2-methoxy-4-[6-oxo-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-4-yl]phenoxy)quinoline-5-carboxylate;

- 4-(3-methoxy-4-phenoxyphenyl)-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-{3-bromo-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 3-*tert*-butyl-4-(4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;
- 4-{4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 5 3-*tert*-butyl-4-(2-methyl-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;
- 4-{4-[3-methoxy-5-(trifluoromethyl)phenoxy]-3-methylphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-{3-fluoro-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-{4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]-3-(trifluoromethoxy)phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-{4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 10 4-[3-(trifluoromethoxy)-4-[2-(trifluoromethyl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 3-*tert*-butyl-4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzoic acid;
- 3-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-5-(trifluoromethyl)benzoic acid;
- 4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 15 4-{3-methoxy-4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-[4-(2,4-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-[4-(2-*tert*-butyl-4-ethylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-[4-(2-*tert*-butyl-4-methoxyphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-[4-(2-*tert*-butyl-4-methylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 20 4-[4-(4-bromo-2-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-(2-methoxy-4-{6-oxo-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-3-(trifluoromethyl)benzonitrile;
- methyl 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-
- 5-carboxylate;
- ethyl 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-

- 5-carboxylate;
- 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-*N,N*-dimethyl-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide;
- 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-*N,N*-diethyl-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-5-carboxamide;
- 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-1*H*,2*H*,3*H*,4*H*,6*H*-pyrrolo[3,4-*b*]pyridin-2-one;
- 4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 4-{4-[2-(difluoromethyl)-4-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 10 (+)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- (-)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- (+)-4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- 15 (-)-4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- (+)-4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- (-)-4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;
- (+)-4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one; and,
- 20 (-)-4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one.

15. The compound according to claim 1, which is

(+)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one; or,

(-)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one.

16. Medicament characterized in that it comprises a compound of Formula I according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof.

5

17. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for use in therapy.

18. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the therapeutic and / or prophylactic treatment of ERR α -mediated diseases or conditions.

10

19. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the treatment of ERR α -mediated cancer.

15

20. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the treatment of at least one condition selected from: lung cancer; melanoma; endometrial cancer; and, acute myeloid leukemia.

21. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the treatment of at least one condition selected from: breast cancer; bladder cancer; prostate cancer; pancreatic cancer; colorectal cancer; and, ovarian cancer.

20

22. Compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof for the treatment of Type II diabetes mellitus.

25

23. Pharmaceutical composition which comprises a compound of Formula I according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

24. Pharmaceutical composition according to claim 23, which further comprises at least one additional therapeutically active agent.